Actively Recruiting
The Role of Furosemide Stress Test in the Intensive Care Clinic
Led by Gulhane Training and Research Hospital · Updated on 2026-01-12
140
Participants Needed
1
Research Sites
73 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
AKI causes high mortality and morbidity, especially in critically ill patients, and prolongs the patient's stay in the intensive care unit. Due to the high morbidity and mortality associated with AKI, many researchers are studying several new biomarkers for earlier detection of AKI, determination of etiologies, and prediction of outcomes. However, the use of these new biomarkers may be limited due to reimbursement issues. In addition to the therapeutic role of furosemide in fluid balance, blood pressure control, and hypercalcemia management, Chawla et al. recommend the furosemide stress test (FST) as a tool to predict AKI progression. Designing a test that predicts the probability of AKI progression will help us make better decisions regarding the optimal timing of RRT initiation. In this study, we aimed to evaluate the feasibility of using the FST test in determining the progression of AKI in patients hospitalized in the intensive care unit and the need for RRT using the noninvasive procedure furosemide stress test.
CONDITIONS
Official Title
The Role of Furosemide Stress Test in the Intensive Care Clinic
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Meet KDIGO criteria for acute kidney injury stage 1 or stage 2 within the first 24 hours
- Have sufficient fluid volume with central venous pressure of 6 cmH2O or higher
- Be male or female aged 18 years or older
You will not qualify if you...
- Pregnant patients
- Hospitalization due to intoxication
- History of liver or kidney transplant
- Glomerular filtration rate below 30 ml/min/1.73m2
- Active bleeding
- Obstructive uropathy
- Need for urgent renal replacement therapy due to severe complications
- Already evaluated as KDIGO acute kidney injury stage 3
- Received renal replacement therapy in the last 30 days
- Diagnosis of chronic kidney disease
- Pulmonary embolism
- Low albumin levels (hypoalbuminemia 2.5 g/dl or less)
- Receiving cephalosporin treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Gulhane Training and Research Hospital
Ankara, keçiören, Turkey (Türkiye), 06010
Actively Recruiting
Research Team
M
mete e erdemir, intensive care specialist
CONTACT
G
gürhan T taşkın, Associate Professor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SCREENING
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here